Skip to main content
. Author manuscript; available in PMC: 2018 Jul 7.
Published in final edited form as: Lancet HIV. 2018 Jun;5(6):e329–e334. doi: 10.1016/S2352-3018(18)30045-6

Figure 1.

Figure 1.

Figure 1.

Sensitivity analysis of averted infections ratio (AIR) in Partners PrEP Study supposing there was no placebo arm. The estimated AIR and corresponding lower 5% CL are plotted as a function of (A) the assumed placebo incidence rate and (B) the assumed effectiveness of TDF-FTC.

Footnote

Dashed line shows the actual values observed in Partners PrEP Study. In actual applications of this approach this information would not be available.

Dotted line shows unobserved value corresponding to AIR of 50%.